Pemetrexed via Ommaya for lung cancer in brain lining
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This study tests whether a drug called pemetrexed, given directly into the fluid around your brain through a small implanted device, is safe and effective for treating lung cancer that has spread to the lining of the brain. It is for people whose cancer has a specific genetic change (EGFR, ALK, or ROS1) and who have already tried standard targeted pills that no longer control their disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-squamous non-small cell lung cancer, and tests show a change in the EGFR, ALK, or ROS1 gene.
- Your cancer has spread to the lining of your brain or spinal cord (called meningeal metastases).
- You have already tried and not responded to the standard targeted therapy pills for your gene change (like at least three lines of EGFR drugs if you have EGFR).
- You are able to have a small device (Ommaya reservoir) placed under your scalp to give medicine directly into the fluid around your brain.
- You do not have severe infections (like uncontrolled hepatitis B or HIV), severe organ problems (heart, kidney, liver), very low blood counts, or active bleeding.
- If you are able to have children, you agree to use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This trial tests if adding an injected chemotherapy drug (pemetrexed) to a targeted oral pill (like osimertinib) works better than the pill alone for patients with lung cancer that has spread to the brain and spinal cord lining.
This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This trial tests a chemotherapy drug called thiotepa, given through a small device placed under the scalp (Ommaya reservoir) that delivers the drug directly into the spinal fluid. It is for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord and who have stopped responding to certain targeted therapies.
Hear when a new Leptomeningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.